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This thesis describes the preparation of pyrazolo[1-5-a]-1,3,5-triazine analogs of the Ca2+ 
channel agonist and cyclin-dependant kinase inhibitor (R)-roscovitine. Initially, efforts to 
improve the published synthetic route to these analogs were investigated. Subsequently, several 
analogs with the pyrazolotriazine core were prepared and evaluated for agonist properties. 
Preliminary results suggest that this modified core retains and in some cases improves agonist 
behavior. A substantial increase in both the Ca2+ tail-current integral and the decay time constant 
tau were observed with the most active analogs MF-06 and MF-17. Modifications to the C-8 
alkyl and C-2 aminobutanol sidechains did not improve agonist activity. 
Synthesis of (R)-Roscovitine Analogs as Potential Treatments for Lambert-Eaton 
Myasthenic Syndrome 
Michael Frasso, M.S. 
University of Pittsburgh, 2014
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1.0  SYNTHESIS OF (R)-ROSCOVITINE ANALOGS AS POTENTIAL 
TREATMENTS FOR LAMBERT-EATON MYASTHENIC SYNDROME 
1.1 INTRODUCTION 
1.1.1. Synaptic Vesicle Release at the Neuromuscular Junction 
Disorders of the neuromuscular junction (NMJ) affect approximately 20 per 100,000 people. The 
true occurrence rate is difficult to determine due to lack of rigorous diagnosis. These diseases 
decrease the quality of life for affected individuals by compromising muscle strength. 
Myasthenia gravis and Lambert-Eaton myasthenic syndrome (LEMS) are the most common 
NMJ disorders, affecting neurotransmitter reception and Ca2+ flow, respectively. Normal signal 
transmission at the skeletal NMJ is triggered by axon terminal depolarization, during which 
voltage-gated calcium channels (VGCCs) permit the influx of Ca2+. This activates synaptic 
vesicle (SVs) binding to the axon terminal membrane and subsequent release of acetylcholine 
(ACh).  
Due to the rapidity with which transmitter release takes place, SVs must already be 
docked near the axon terminal membrane at the time of Ca2+ influx.1 Prior to Ca2+ entry, VGCCs 
must be recruited to the “active zone” where transmitter release takes place (Figure 1). Rab3 and 
Rab27 are vesicle membrane-bound GTP-binding proteins. These proteins bind to Rab3-
 2 
interacting molecule (RIM), which forms the vital tether between SV and VGCC. Ca2+ channel 
recruitment is aided by RIM-BP, which binds to both RIM and the channel. Absence of either 
RIM of RIM-BP results in decreased Ca2+ influx at active zones, probably due to decreased 
localization of the requisite channels.2-4 RIM also binds an additional priming factor, Munc-13, 
which promotes SNARE complex assembly by altering the conformation of syntaxin-1 (vide 
infra).5  
 
Figure 1: Proteins involved in neurotransmitter release at axon terminal active zones.6 Reproduced with 
permission from Elsevier. 
Additionally, the SV is tethered by the soluble N-ethylmaleimide sensitive fusion protein 
(NSF) attachment receptor protein (SNARE) complex (synaptobrevin/VAMP, syntaxin-1, and 
 3 
SNAP-25), as well as Munc-18. Plasma membrane-bound syntaxin-1 in its closed conformation 
is initially bound to Munc-18. Munc-13 then promotes a conformational change in syntaxin-1 to 
the open state, which triggers SNAP-25 association, as well as interactions with 
synaptobrevin/VAMP. This action pulls the SV in close proximity to the plasma membrane.7 
Upon entry of Ca2+ into the synaptic terminal, vesicular membrane-bound synaptotagmin-
1 (Syt-1) is thought to act as a Ca2+ sensor and mediates fusion pore opening of the docked SVs. 
This may occur as a result of a conformational change that places the two membranes in close 
proximity.8 Deletion of the Syt-1 gene has been shown to decouple rapid exocytosis from Ca2+ 
entry.9-11 Additionally, complexin has also been shown to be important in this process, but its 
exact role has not been determined.6   
1.1.2 Voltage-Gated Calcium Channels: Structure and Subtypes 
The previous discussion shows that Ca2+ influx is the key event that triggers SV exocytosis. The 
channels responsible for this usually contain four major subunits, namely α1, α2δ, β, and γ  
(Figure 2). The α1 subunit forms the central pore of the complex and is the primary determinate 
of the channel’s properties. The other subunits all function to fine-tune the activation and 
deactivation kinetics, with the β subunit having the most substantial effect.12,13 The α1 subunit is 
comprised of four homologous domains with six membrane-spanning helices each. The fourth in 
each contains several positively charged arginine and lysine residues and is thus thought to be 
responsible for voltage sensing. The loop connecting the fifth and sixth transmembrane helix in 
each domain lines the interior of the pore and is thought to confer ion selectivity.13,14 
Intriguingly, three amino acid mutations in this region from a closely related Na+ channel alters 
the ion selectivity from Na+ to Ca2+.15,16 
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Figure 2: (Top) Schematic representation of high-voltage activate (HVA) and low-voltage activated (LVA) 
VGCCs. (Bottom) A more detailed view of the HVA channel.13 Reproduced with permission from Elsevier. 
At least ten different α1 subunits have been identified to date and it is this variability that 
leads to the different VGCC subtypes.14 There are two broad categories of VGCCs based on the 
requisite departure from the resting membrane potential. High voltage activated (HVA) channels 
require large departures from the resting membrane potential (from -70 mV to 30-50 mV), 
whereas low voltage activated (LVA) channels require much smaller perturbations for activation 
(-70 mV to -55 mV to -20 mV).17 Each of these categories can then be subdivided into smaller 
groups as well. HVAs channel subtypes include L-, R-, N-, and P/Q-types. L- and R-type 
 5 
channels are not thought to play a prominent role in synaptic transmission at adult NMJs, but 
have been implicated in vesicle release in developing muscle and memory, respectively.18-20 
N-type channels are primarily found in neuronal tissue, particularly in dendrites and 
synaptic terminals.21-23 Their localization suggests a role in neurotransmitter release, which is 
indeed the case at some synapses, mostly in the central nervous system.24 Inhibition of these 
channels has been of interest, particularly in the treatment of neuropathic and chronic pain.25,26 
While their role in neurotransmitter release at the amphibian NMJ has been demonstrated,27,28 
they do not appear to facilitate the same process in mammals.20 
P/Q-type channels are closely related to N-type channels and can be found in many of the 
same areas, and mice lacking the requisite gene suffer from various forms of ataxia.13 These 
channels are primarily responsible for the release of neurotransmitters in the mammalian 
NMJ20,29 and are thus of interest in the treatment of certain disorders, in particular LEMS. 
1.1.3 Lambert-Eaton Myasthenic Syndrome 
LEMS is an autoimmune disorder of the NMJ that results from an antibody mediated removal of 
presynaptic P/Q-type VGCCs.20 This removal effectively decreases the Ca2+ concentration in the 
axon terminal following depolarization, and thus decreases ACh release. Consequently, patients 
typically exhibit muscle weakness, particularly proximal leg weakness and fatigability as the 
most common early symptoms. Dry mouth, impotence in men, and various other autonomic 
abnormalities can occur as later symptoms,30,31 as well as oculobulbar (muscles of the eye and 
eyelid) weakness that commonly occurs in the related myasthenia gravis.31,32 An upregulation of 
N- and L-type channels is also observed at affected NMJs, and this may be the reason that the 
 6 
effects of LEMS are not more severe.33 Repeated stimulation partially restores muscle function, 
due to the presumed accumulation of Ca2+ through the reduced number of channels.34  
The first recorded case of LEMS was reported in 1953 by Anderson35 in association with 
a lung tumor, and subsequently, it has been found that over half of the diagnosed cases appear as 
a paraneoplastic syndrome of small-cell lung carcinomas.36 The majority of remaining cases are 
idiopathic in nature, and less commonly the disorder has been associated with other types of 
cancer.30 
There is no cure for LEMS and treatment options are both limited and symptomatic only.   
The first strategy is to treat the tumor in relevant cases as this is a more serious threat to the 
patient’s health and can provide symptomatic relief.34,37,38 As LEMS is an autoimmune disorder, 
immunomodulation of various types can be used as well. Plasmapherisis (separating of patient’s 
plasma from other blood components and replacing it with other plasma) and administration of 
immunoglobulin intravenously have been shown to be effective in a number of cases though 
these have obvious disadvantages such as inconvenience to the patient and limited 
effectiveness.31,39,40 Oral dosage of prednisolone (Figure 3) has also been found to be 
effective.31,41 Even with these treatments, impaired muscle function persists.34 
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Figure 3: Structures of LEMS pharmaceuticals. 
 
Blocking neurotransmitter degradation through acetyl cholinesterase inhibitors has also 
been used in the treatment of LEMS. Physostigmine, neostigmine and pyridostigmine (Figure 3) 
have been used most frequently, but this therapy seems to be rather ineffective if used alone. 
When used in combination with 3,4-diaminopyridine (3,4-DAP) (vide infra) (Figure 3), 
effectiveness is increased, but improvement is modest at best.31  
The final and most widely successful treatment option is increasing neurotransmitter 
release. This has been achieved indirectly with K+ channel blockers. A decrease in channel 
activity allows for prolonged axon terminal depolarization, thus longer VGCC channel open 
times and a larger influx of Ca2+, resulting in increased neurotransmitter release.42,43 Guanidine 
has been used but a low dose limit and a wide variety of side effects including bone marrow 
suppression and renal failure have prevented its widespread use.44,45 The most successful 
treatment in this category is 3,4-DAP. At higher dosages, 3,4-DAP shows side effects including 
parethesia (numbness or “pins and needles” sensation), insomnia, and occasionally, seizures.31,46 
3,4-DAP is currently available through a free distribution program, but this has been endangered 
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by clinical trials undertaken by a company that is pursuing patent protection. This has raised 
concerns about future affordability of the treatment for patients.47  
1.1.4 Calcium Channel Agonists as Potential Therapeutics 
One potential therapeutic strategy that has not yet been exploited is the direct activation of 
VGCCs. Since LEMS patients have fewer P/Q-type calcium channels at the NMJ, increasing 
flux through the remaining channels may mimic having a normal number of channels and reduce 
muscle weakness. (R)-Roscovitine (Figure 4) was initially developed as a cyclin-dependent 
kinase (cdk) inhibitor,48 and is currently in various clinical trials as a cancer therapeutic. (R)-
Roscovitine also shows mild VGCC agonist activity, specifically towards P/Q- and N-type 
channels, that is unrelated to its cdk inhibition properties.49-51 It should also be noted that mild 
VGCC deactivation behavior has been observed, presumably due to a less favored binding to the 
closed state of the channel. Since these channels are primarily responsible for neurotransmitter 
release, (R)-roscovitine is a good lead for further development.  As cdk inhibition would cause 
undesired side effects if (R)-roscovitine were used to treat LEMS, our group aims to develop 
analogs that would display both decreased cdk inhibition and increased VGCC agonist activity.52  
 
Figure 4: I) Structure of parent compound (R)-roscovitine. II) Zones for modification of parent compound. 
N
NN
N
HN
N
H
Ph
OH
(R)-Roscovitine
I
N
NN
N
R1
HN
N
H
R2
R3
Zone B
Zone A
Zone C
Zone D
II
 9 
Initially, zones A and B (Figure 4) were selected for modification. Only conservative 
modifications were tolerated in zone A, with many derivatives becoming too insoluble to test as 
the size of the substitution was increased. Subtle modification of the isopropyl group to the n-
propyl group in zone A gave a 22-fold decrease in cdk 2 inhibition (Fig 5, KB-08), presumably 
due to greater flexibility, while giving a 2-fold increase in N-type channel agonist activity. 
Various alkyl and aryl replacements of the phenyl group in zone B with the exception of the (2-
methyl)-5-thiophenyl derivative ML-50 (Figure 5) completely abolished N-type channel agonist 
activity. Further modification in zone A showed the importance of the isopropyl group in cdk 2 
inhibition, with methylated analog GV-05 (Fig. 5) showing an 11–fold drop in activity compared 
to ML-50, although a 2-fold drop in N-type channel agonist activity was also observed. 
Ultimately, GV-58 was found to be the most effective analog with a 22-fold decrease in cdk 2 
inhibition and a 4-fold increase in N-type channel agonist activity. Additionally, GV-58 was 
found to restore partial function at a LEMS passive transfer mouse model NMJ and to have a 
synergistic effect with 3,4-DAP.53,54 For this reason, GV-58 was selected for further 
development 
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Figure 5: Structures of (R)-roscovitine and important previous analogs.52 
1.2 RESULTS AND DISCUSSION 
1.2.1 Chemistry  
The pyrazolo[1,5-a]-1,3,5-triazine core has been shown to have comparable cdk 
inhibition properties in (R)-roscovitine analogs,55 but its Ca2+ agonist properties are unknown. 
Since this scaffold has been shown to be a good bioisostere of the purine scaffold of (R)-
roscovitine,55,56 we elected to pursue it for structure-activity relationship (SAR) studies. Scheme 
1 shows the published method for preparing a modified (R)-roscovitine analog.55 Addition of 3-
aminopyrazole into ethoxycarbonyl isothiocyanate gave thiourea 1 which was immediately 
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cyclized under basic conditions, then methylated with methyl iodide to intermediate 2. The 
aniline activating group was installed via a phosphorus oxychloride (POCl3) mediated 
chlorination followed by aminolysis (3). Friedel-Crafts acylation, Grignard addition to the 
resulting ketone, and a deoxygenation with NaBH4/trifluoroacetic acid (TFA) allowed for the 
installation of the isopropyl moiety in compound 5. Displacement of the aniline with 
benzylamine in ethanol at 90 oC, oxidation to the sulfone, and aminolysis gave the desired 
pyrazolo[1,5-a]-1,3,5-triazine analog of (R)-roscovitine (8). 
 
Scheme 1: Published preparation of a pyrazolo[1,5-a]-1,3,5-triazine analog of (R)-roscovitine.55 
 
While preparing 8, several weaknesses in the synthetic route became apparent. First, the 
preparation of 3 was found to give highly variable results, with yields ranging from 0-70%, 
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possibly due to the instability of the intermediate chloride. In order to circumvent this issue, a 
direct preparation of 3 was investigated. Various peptide coupling reagents were tested (Table 1). 
PyBOP, PyBrOP, and TFFH with Et3N gave little to no conversion (entries 1-3). Changing the 
base to N,N-dimethylaminopyridine (DMAP) with PyBrOP showed slightly improved results 
(entry 4). Hexachlorocyclophospazene (HCCP) has been shown to be effective in similar 
systems,57 and upon treating 2 with HCCP and N,N-diisopropylethylamine (DIPEA) in 
acetonitrile, a 65% yield of 3 was obtained (entry 5). Changing the base to DMAP did not 
improve the yield. The conditions in entry 5 were selected for further use and proved to be more 
reliable and operationally simple than the original conditions, as handling of large quantities of 
POCl3 was not required.  
Table 1: Coupling reagents and conditions screen 
 
  a MeCN used as solvent 
 
The oxidation of 6 to the intermediate sulfone was also found to be inefficient, giving 
only a 30% yield using m-CPBA (Scheme 1). Altering the conditions to Oxone® with sodium 
N
N
NHN
S
2
N
N
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N
S
3
O
N-Methylaniline
Reagent, base
CH2Cl2
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15
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N
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P
N P N
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Cl Cl
Cl
ClCl
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4
3
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1
2
6 HCCP DMAP 47a
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bicarbonate in acetone/water58 gave the desired sulfone as the only product. This material could 
be used in the following aminolysis after a simple aqueous workup. Subsequently, it was found 
that the sodium bicarbonate was unnecessary. 
The installation of the alkyl sidechain in zone A was targeted as the final area for 
improving the synthesis, as in the published process this requires three steps (Scheme 1). The 
previously used Friedel-Crafts acylation was high yielding, so a modified procedure leading 
directly to alkylated products was chosen. It had been shown that standard Friedel-Crafts 
alkylations using alkyl halides were ineffective,55 therfore methods using alcohols were 
investigated. The first conditions used were 1,1-phenylethanol and p-toluenesulfonic acid 
(PTSA) in dichoromethane at 60 oC59 and showed a trace of desired product 9 (Table 2, entry 1). 
Stochiometric Lewis acid conditions with BF3.Et2O at 0 oC afforded none of the desired material 
(entry 2).60 Catalytic Lewis acid processes using 1 mol% of La(OTf)3 or Sc(OTf)3  in 
nitromethane at 100 oC60 showed slightly better results, with Sc(OTf)3 being superior (entries 3-
4). Increasing the catalyst loading to 10 mol% showed dramatically improved results, giving a 
60% isolated yield (entry 5). Further increasing the catalyst loading to 20 mol% offered no 
improvement and increasing the amount of alcohol or changing the solvent resulted in decreased 
yield (entries 6-10). 
 14 
Table 2: Conditions screen for Friedel-Crafts reaction. 
 
a 100 mol%; b 1 mol%; c 20 mol% Sc(OTf)3 conversion by 1H NMR as previous entry; d 200 mol% alcohol. 
 
With optimized conditions identified, we sought to explore the scope of the 
transformation (Table 3). Isopropanol showed no trace of product 10 even after an extended 
reaction time, probably due to lack of an adequately stabilized carbocation (entry 1). In an effort 
to increase intermediate carbocation stability, primary allylic alcohols were used and also proved 
to be ineffective, even with the added stabilization of a phenyl ring (entries 2-4). However, a 
secondary allylic alcohol gave a 53% yield of product 14 (entry 5). Surprisingly, two additional 
secondary allylic alcohols gave only trace amounts of product, with a phenyl ring again failing to 
aid the reaction (entries 6-7). A tertiary allylic alcohol (entry 8) and various propargylic alcohols 
failed as well (entries 9-12). 
N
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Temp (oC) Yield (%)
trace100
 Catalyst Solvent
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8
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Table 3: Scope of Friedel-Crafts alkylation. 
  
 
 Since compound 14 could be prepared in moderate yield, we decided to investigate a 
cross metathesis to expand access to analogs at the 8-position (Table 4). A pendant double bond 
in this position following cross metathesis would allow for the preparation of several different 
analogs from a single starting material via hydrogenation, dihydroxylation, or epoxidation 
followed by nucleophilic ring opening. Unsaturated ring analogs have not been explored to date, 
so methylenecyclohexane was used in the initial trial with Grubbs second-generation catalyst in 
dichloromethane at 40 oC. (entry 1) No reaction was observed. Since 1,1-disubstituted alkenes 
N
N
NN
N
S
Alcohol
Sc(OTf)3, MeNO2,
 100 oC
N
N
NN
N
S
R2
R1
Alcohol Yield (%)
OHEt
OH
OH
OHPh
OH
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OH
OH
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Ph
0
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53
5
trace
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0
0
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0
Alcohol Yield (%)Product
17
Product
10
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12
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18
19
20
21
3 10-21
Entry
1
2
3
4
5
6
Entry
7
8
9
10
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12
OH
trace15
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are known to be more difficult substrates for cross metathesis reactions,61 simple terminal 
alkenes were used in further experiments to find optimal conditions. First, 1-hexene was used 
and showed some conversion under the same conditions (entry 2), but products were inseparable 
from the starting material. In order to both aid in product separation and remove the concern that 
1-hexene evaporates during the reaction, 1-octene was used (b.p. ~60 oC vs. ~120 oC), but this 
gave similar results (entry 3). Ethylene gave no reaction (entry 4).  
Table 4: Cross metathesis with 14. 
 
         a products could not be separated. b 75 oC, µW, 2 h.  
 
  
It was hypothesized that the thioether was poisoning the catalyst, so similar cross 
metathesis reaction were performed with the corresponding sulfone (prepared using previously 
established oxidation conditions with Oxone®, vide supra). No significantly improved results 
were obtained. Due to these difficulties, cross metathesis efforts were abandoned and the original 
method for installing the alkyl sidechain was used in the analog synthesis.  
N
N
NN
N
S Grubbs' II,
CH2Cl2, 40 oC, 20 h
N
N
NN
N
S
R1
R214
R1
R2
Alkene Yield (%)
0
----a
----a
----a,b
0
Alkene Yield (%)ProductProduct
22
1-hexene 23
24
25
26
1-octene
1-octene
ethylene
22-26
Entry
1
2
3
Entry
1
2
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The final route toward pyrazolo[1,5-a]-1,3,5-triazine analogs can be seen in Scheme 2. 
The aniline activating group was installed by the modified HCCP coupling procedure giving 3 
(Scheme 1) in good yield. Friedel-Crafts acylation was then performed using one of three acyl 
chlorides in good yields (75-80%). Reduction of ketones 4b and 4c proved to be unexpectedly 
difficult. Using TFA/NaBH4 gave only 40% of 5b, even after extended reaction time. It was 
noted that none of the intermediate alcohol was observed, suggesting that ketone reduction is 
sluggish in this system. Partial reduction of ketone 4b using LiBH4 generated in-situ followed by 
deoxygenation with TFA/NaBH4 gave the desired product 5b in 87% yield.  Reduction of ketone 
4c proved to be even more challenging. The above method for reducing 4b was found to be 
ineffective, giving only trace amounts of the desired product. Standard conditions using LiAlH4 
or LiHBEt3 in THF or Wolff-Kishner reductions prompted decomposition. Luche reduction 
conditions gave recovered starting material, probably due to poor solubility of the starting 
material. Similarly, reductions with LiAlH(OtBu)3  in THF or Et3SiH in TFA were unsuccessful 
and also returned starting material. Finally, it was found that reduction with BH3.THF gave an 
acceptable 41% yield of 5c. Displacement of the aniline activating group with the desired amine 
gave compounds 6a-6d in moderate yield.   
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Scheme 2: Preparation of intermediates 6a-6d. 
Oxidation of the thioethers 6a-6d with Oxone® in acetone/water followed by aminolysis gave 
the desired final products in moderate to good yields (Table 5). 
,  SnCl4
CH2Cl2, 85 °C, 17 h
R = Me, 80% (4a)
R = Et, 78% (4b)
R = Cyclopropyl, 75% (4c)
N
N
NN
N
S
O
R
Cl R
O
N
N
NN
HN
S
R
R = Et (5b)
 NaBH4, LiCl, 1:1 DCM:EtOH, 15 h, then
 NaBH4, TFA, CH2Cl2, 4h
87%
or R = Cyclopropyl (5c)
BH3.THF, THF, 22 h
41%
N
N
NN
N
S
R
S NH2
KF,  EtOH, 
 130 °C, 20 h
R = n-Pr, 48% (6c)
R = (CH2)CHCH2, 30% (6d)
3
R'
MeMgBr, THF, 0.75 h
then NaBH4, TFA, CH2Cl2, 2 h
R = Me, 95% (5a)
N
N
NN
N
S
R' NH2
KF, EtOH, 130 oC
R' = Ph, 52% (6a)
R' = 5-Methylthiophen-2-yl, 49% (6b)
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Table 5: Preparation of screening samples. 
 
Future synthetic endeavors may be directed towards simplifying the synthesis in a 
different manner (Scheme 3). The two amine sidechains could be installed selectively with the 
same activating group at the 2- and 4-positions due to the difference in reactivity. This could 
potentially bypass the aniline activating group and the sulfur methylation/oxidation steps of the 
current synthetic route. The activation could be performed by either dichlorination or 
dimethylation of II, which can be prepared from the addition of the requisite 3-aminopyrazole 
into ethoxycarbonyl isocyanate followed by cyclization.  
N
N
NN
HN
N
HR
R'
 
 KF, dioxane
Oxone
 Acetone:H2O, 12 h R''
N
N
NN
HN
S
R
R Yield (%)
57
11
43
27
n-Pr
(CH2)2CH2
n-Pr
n-Pr
R'' Temp (oC)
OH 140
Product
MF-17
MF-27
MF-59
MF-71
OH
CF3
140
120
OEt
O
OH 120
57n-PrMF-21 OH 120
R'
6a-6d
R = i-Pr, n-Pr, (CH2)2CH2
R = Ph, 5-Methylthiophen-2-yl
8
R'
i-Pr Ph 82OH 140
MF-06 i-Pr 5-Methylthiophen-2-yl
5-Methylthiophen-2-yl
5-Methylthiophen-2-yl
5-Methylthiophen-2-yl
5-Methylthiophen-2-yl
5-Methylthiophen-2-yl
68OH 140
Entry
1
2
3
4
5
6
7
N
N
NN
HN
SO2Me
R
R'
7a-7d 8, MF-XX
H2N R""
20 
Scheme 3: Retrosynthesis for potential future synthetic route. 
1.2.2 Biological Results 
Preliminary results indicate that the pyrazolo[1,5-a]-1,3,5-triazine scaffold is beneficial for 
increasing Ca2+ current through N-type channels. Analogs were tested in whole-cell perforated 
patch-clamp assays of tsA-201 cells expressing N-type channels.51,53 Cells were stimulated at 
+60 mV and tail-current integrals measured while holding the cells at -60 mV (integrals 
normalized to both peak tail-current amplitude for each compound and to control). Figure 6 
shows normalized tail-current integrals for the prepared analogs. The pyrazolotriazine analog 
MF-17 shows slightly improved activity compared to its purine analog GV-58, demonstrating 
that this modification is tolerated. Altering the alkyl sidechain in zone A to the 
cyclopropylmethylene in MF-71 was found to be detrimental to agonist activity, whereas the 
isopropyl analog MF-06 was found to be highly active. This is in agreement with prior data 
suggesting that activity is highly sensitive to zone A substitutions. Modifications of the 
aminobutanol sidechain in zone C proved to have a deleterious effect both in the case of 
trifluoromethyl analog MF-59 and dimethyl analog MF-21. Cyclopropyl ester MF-27 
completely abolished activity and actually promoted channel deactivation (data not shown). 
Interestingly, SCT-62, the enantiomer of GV-58, retained some activity. To date, only the 
aminobutanol sidechain has been found to convey activity, with the (R)-enantiomer giving 
superior results. 
N
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N
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X
X
N
N
H
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O
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H
N
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Figure 6: Normalized tail-current integrals for various analogs. All compounds were tested at 50 µM.  Data 
for GV-58 and (R)-roscovitine were previously published. All other data are unpublished. 
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Decay time constants (tau) were also investigated and provide a measure of mean channel 
open times (Figure 7).51 The four most active compounds from Figure 6 all show significantly 
longer open times than both the control and (R)-roscovitine treated channels, with MF-06 
showing the largest tau value. Interestingly, enantiomers GV-58 and SCT-62 show similar tau 
values, yet noticeably different tail-current integral areas. Further investigation is needed to 
determine the origin of this effect. 
Figure 7: Decay time constants for most active analogs. All compounds were tested at 50 µM. Data 
are unpublished. 
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An interesting difference arises when comparing MF-17 and MF-06 with purine analogs 
GV-58 and ML-50 (Figure 8). The n-propyl analogs MF-17 and GV-58 show similar tail-
current integrals, whereas isopropyl analog MF-06 shows a ~67% increase over ML-50. 
Figure 8: Comparison of agonist effects between zone D purine and pyrazolotriazine analogs. All 
compounds were tested at 50 µM except ML-50, which was tested at 100 µM. Data for (R)-roscovitine, ML-50, and 
GV-58 have previously been published.53 Other data are unpublished. 
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One potential explanation of the difference in activity between the two pairs of analogs 
(ML-50/MF-06 have a large difference in activity, GV-58/MF-17 have near identical activity) is 
the difference in the rotational energy barrier between the two sidechains. Molecular mechanics 
calculations were performed to investigate this possibility. Sidechains in zones B and C were 
truncated to methylamines to simplify calculations. The n-propyl substitutions in zone A were 
truncated to ethyl in order to eliminate artificial inflation of the rotation energy barrier due to 
locking the methyl-methylene bond in this sidechain. The conformer distribution was calculated 
and the minimum energy conformer selected. All torsion angles were then held constant and 
single-point energies calculated for rotation about the indicated bonds.  Figure 9 and Figure 10 
show the plot of relative energy versus the dihedral angle shown in either blue or red for the pairs 
of analogs.  
Figure 9: Steric energy of rotation for isopropyl sidechains with simplified structures. Torsion angle of 
interest is highlighted in either blue or red. 
N
NN
N
HN
N
H
H
N
N
NN
HN
N
H
HA B
0	  5	  
10	  15	  
20	  25	  
30	  35	  
40	  45	  
50	  
-­‐200	   -­‐150	   -­‐100	   -­‐50	   0	   50	   100	   150	   200	  
Re
l.	  
En
er
gy
	  (k
J/
m
ol
)	  
Dihedral	  Angle	  
A	  
B	  
25 
For purine derivatives A and A’ (simplified structures for ML-50 and GV-58) barriers 
are larger than in the corresponding pyrazolotriazine, possibly due to the decreased bond length 
(1.456 Å vs. 1.498 Å in A and B, Figure 9; 1.446 Å vs. 1.487 Å in A’ and B’, Figure 10) 
between the ring and sidechain. However, the isopropyl derivatives A and B show a larger 
difference (~30 kJ/mol) in rotational energy barriers than the unbranched analogs A’ and B’ (~20 
kJ/mol, ~7 kJ/mol, two different barriers). This increased energy penalty may prevent ML-50 
from attaining the preferred conformation for receptor binding. Since energy barriers are smaller 
in the n-propyl analogs, they may be able to fold into similar active conformations, and thus 
giving similar agonist activities. 
Figure 10: Steric energy of rotation for unbranched sidechains with simplified structures. Torsion angle of 
interest is highlighted in either blue or red. 
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One potential method to test this hypothesis would be to prepare the pyrazolotriazine of 
GV-05 and compare agonist activities (methyl group in zone A, see Figure 5 for structure). The 
rotational energy barrier difference between these two compounds should be nearly identical, 
and should thus have very similar activities if the rotation energy barrier is a major determinant 
of activity. 
Figure 11: Decrease in peak amplitude of Ca2+ current with repeated stimuli for the four most 
active analogs. All compounds were tested at 50 µM. Data are unpublished. Cont = control. Contronl is peak 
amplitude without added compound.
Effects on peak current amplitudes over multiple stimuli were also investigated to 
determine the antagonist effects over time of the four most active analogs (Figure 11). Purine 
27 
analogs GV-58 and SCT-62 show stronger deactivation, with peak amplitude decreasing to 
~92% of the first stimulus by the third stimulus. In contrast, the pyrazolotriazine analogs showed 
less deactivation, with MF-06 having no significant effect on peak amplitude. 
1.2.3 Conclusion 
Several pyrazolo[1,5-a]-1,3,5-triazine analogs of (R)-roscovitine have been prepared. 
Preliminary results suggest this modification may beneficial for increasing Ca2+ current through 
N-type VGCCs and previous results show that this correlates well with a similar behavior in P/
Q-type channels. Also, these analogs show decreased or absence of VGCC deactivation over 
time. Thus, these compounds may prove useful in treating Lambert-Eaton myasthenic syndrome. 
In the future, the most promising candidates will be tested for cdk2 inhibition to complete the 
SAR analysis. 
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2.0  EXPERIMENTAL SECTION 
2.1 GENERAL 
All moisture-sensitive reactions were performed using syringe-septum techniques under 
an atmosphere of either dry N2 or Ar unless otherwise noted. Tetrahydrofuran and diethyl ether 
were purified by distillation over sodium/benzophenone under a dry N2 atmosphere. 
Dichloromethane was purified by distillation from CaH2. All other materials were obtained from 
commercial sources and used as received unless otherwise stated. Reactions were monitored by 
TLC analysis (pre-coated silica gel 60 F254 plates, 250 µm layer thickness) and visualized by 
using UV lamp (254 nm) and/or by staining with KMnO4 solution (3.0 g KMnO4, 4.0 g K2CO3, 
in 200 mL H2O and 4 mL 5% NaOH). Flash column chromatography was performed with 40-63 
µm silica gel (Silicycle). Infrared spectra were measured on a Smiths Detection IdentifyIR FT-IR 
spectrometer (ATR). All NMR data was collected at room temperature in CDCl3 on a 300, 400, 
or 500 MHz Bruker instrument. Chemical shift per million (ppm) with internal CHCl3 (δ 7.26 
ppm for 1H
 
and 77.00 ppm for 13C) or (CD3)2SO with internal (CH3)2SO  (δ 2.50 ppm for 1H) 
 
as 
the reference. NMR data are reported as follows: chemical shift, multiplicity (s = singlet, bs = 
broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = 
doublet of triplets, qd = quartet of doublets), integration, and coupling constant(s) (J) in Hertz 
(Hz). 
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Whole-cell Ca2+ currents were recorded using the perforated patch-clamp method of tsA-
201 cells transfected with N-type channels.53 The pipette solution contained 70 mM Cs2SO4, 1 
mM MgCl2, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) at pH 7.4. 
Cells were bathed in a saline solution composed of 130 mM choline chloride, 10 mM 
tetraethylammonium chloride, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, at pH 7.4. Patch 
pipettes were prepared with borosilicate glass pulled to a resistance of approximately 1 MΩ. The 
perforating agent was 65 µM amphotericin B. Passive membrane potentials and capacitive 
currents were subtracted form the data. Currents were activated using a tep delpolarization from  
-60 mV to +60 mV, amplified with an Axopatch 200B amplifier, and further analysis performed 
using pClamp 10 software. Tail-current integrals were measured before and after application of a 
compound, with each recording normalized to its peak. Compounds were bath applied at 50 µM 
(except ML-50, 100  µM) with a glass pipette in a 1.5 mL static bath chamber. Each compound 
tested 3-6 times. Control experiments were performed using 0.1-1% DMSO. All experiments 
were performed at room temperature. Tau values were determined by fitting a single exponential 
function to the Ca2+ current decay. 
Molecular mechanics calculations were performed with the Spartan 10 software package 
using the Merck molecular force field (MMFF). Conformer distributions were calculated in the 
gas phase, and the minimum energy conformer selected. All torsion angles in this conformer 
were then locked except the dihedral angle indicated in the figures above and the single point 
energy calculated every 3 degrees of rotation about the indicated angle. 
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2.2 EXPERIMENTAL PROCEDURES 
 
1 
N-Ethoxycarbonyl-N'-(pyrazol-3-yl)thiourea (1).62 A solution of 3-aminopyrazole 
(2.65 g, 31.6 mmol, 1.1 equiv.) in THF (37 mL) was cooled to 0 °C under nitrogen. In a 
dropwise fashion, ethoxycarbonyl isothiocyanate (3.5 mL, 28 mmol, 1.0 equiv.) was added over 
approximately 5 min. The reaction mixture was allowed to stir for 1 h at 0 °C. Solvent was then 
removed under reduced pressure giving crude 1 (6.80 g) as a yellow solid: 1H NMR (CDCl3, 300 
MHz) δ 11.9 (bs, 1 H), 8.28 (bs, 1 H), 7.55 (d, 2 H, J = 2.4 Hz), 7.04 (d, 2 H, J = 2.4 Hz), 4.30 
(q, 2 H, J = 7.1 Hz), 1.34 (t, 3 H, J = 7.1 Hz). 
 
2 
2-(Methylthio)pyrazolo[1,5-a][1,3,5]triazin-4(3H)-one (2).63 A solution of 1 (6.80 g, 
25.4 mmol, 1.00 eq) in 2 N NaOH (52 mL, 104 mmol, 4.1 equiv.) was stirred at room 
temperature for 5 h. The reaction mixture was cooled in an ice bath and 2 N H2SO4 (75 mL, 150 
mmol, 6.0 equiv.) was added in small aliquots. The resulting precipitate was collected by 
vacuum filtration, washed with water, and dried under vacuum to give an off white powder (5.05 
g). This solid was suspended in EtOH (90 mL), and after addition of aqueous 2 N NaOH (23 mL, 
46 mmol, 2.0 equiv.) and methyl iodide (1.4 mL, 22.5 mmol, 1.00 equiv.), the resulting slurry 
was stirred at room temperature for 1.5 h. The reaction mixture was then filtered and the solid 
N
H
N
N
H
N
H
O
S O
N
N
NHN
O
S
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was dissolved in water (225 mL) by stirring for 10 min. After addition of 2 N H2SO4 (13 mL, 26 
mmol, 1.2 equiv.), the resulting solid was filtered, washed with water, and air dried overnight 
giving 2 (2.99 g, 11.8 mmol, 50% over 3 steps) as a white solid that was used in the next step 
without further purification: 1H NMR (DMSO-d6, 400 MHz) δ 12.89 (bs, 1 H) 7.97 (d, 1 H, J = 
1.6 Hz), 6.35 (d, 1 H, J = 2.0 Hz), 2.53 (s, 3 H). 
 
3 
N-Methyl-2-(methylthio)-N-phenylpyrazolo[1,5-a][1,3,5]triazin-4-amine(3).64         
A flame-dried flask was charged with 2 (1.00 g, 5.38 mmol, 1.00 equiv.) and phosphonitrillic 
chloride trimer (2.27 g, 6.46 mmol, 1.20 equiv.). The vial was flushed with argon, and MeCN 
(50 mL) and DIPEA (4.7 mL, 26 mmol, 5.0 equiv.) were added. The reaction mixture was stirred 
for 1 h at room temperature and then treated with N-methylaniline (4.2 mL, 22 mmol, 4.0 
equiv.). The suspension immediately cleared and stirring was continued for 6 h. The solvent was 
removed under reduced pressure and the residue dissolved in dichloromethane (50 mL). The 
organic phase was washed with 1 N HCl (2x20 mL), sat. NaHCO3 (10 mL), and brine (20 mL), 
dried (MgSO4) and concentrated. Purification by chromatography on SiO2 (1:0 to 1:1 to 0:1, 
hexanes:dichloromethane) provided 3 (1.03 g, 3.72 mmol, 69%) as a pale yellow oil that slowly 
solidified: 1H NMR (CDCl3, 400 MHz) δ 7.64 (d, 1 H, J = 2.4 Hz), 7.41-7.36 (m, 3 H), 7.19-7.17 
(m, 2 H), 6.16 (d, 1 H, J = 2.0 Hz), 3.73 (s, 3 H), 2.54 (s, 3 H). 
 
N
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4a 
1-(4-(Methyl(phenyl)amino)-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-8-yl)ethan-
1-one (4a).55 A flame-dried vial was charged with 3 (336 mg, 1.21 mmol, 1.00 equiv.), acetyl 
chloride (0.17 mL, 2.4 mmol, 2.0 equiv.) and 1 M tin(IV) chloride in dichloromethane (6.1 mL, 
6.1 mmol, 5.0 equiv.). The vial was sealed and allowed to heat at 85 °C for 17 h. The reaction 
mixture was then poured over crushed ice, diluted with CHCl3 (12 mL), extracted with CHCl3 
(3x8 mL), washed with water and brine (10 mL each), and dried (MgSO4), and concentrated. 
Purification by chromatography on SiO2 (5:6:1, dichloromethane:hexanes:ethyl acetate) provided 
4a (310 mg, 0.969 mmol, 80%) as a white solid: 1H NMR (CDCl3, 300 MHz) δ 8.07 (s, 1 H), 
7.40-7.37 (m, 3 H), 7.18-7.15 (m, 2 H),  3.74 (s, 3 H), 2.69 (s, 3 H), 2.58 (s,  3 H). 
 
4b 
1-(4-(Methyl(phenyl)amino)-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-8-
yl)propan-1-one (4b). A flame-dried vial was charged with 3 (737 mg, 2.67 mmol, 1.00 equiv.), 
dichloromethane (13 mL), propionyl chloride (0.47 mL, 5.3 mmol, 2.0 equiv.) and 1 M tin(IV) 
chloride (1.6 mL, 13 mmol, 5.0 equiv.). The vial was sealed and heated at 85 °C for 17 h. The 
reaction mixture was then poured over crushed ice, diluted with water (15 mL) and 
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dichloromethane (10 mL) and allowed to stir for 30 min. The layers were separated, and the 
aqueous layer was extracted with dichloromethane (15 mL). The combined organic fractions 
were washed with brine (15 mL), dried (MgSO4), and concentrated. Purification by 
chromatography on SiO2 (1:0 to 95:5 to 9:1, dichloromethane:ethyl acetate) provided 4b (710 
mg, 2.06 mmol, 78%) as a faintly brown solid: Mp 147.6-148.2 °C; 1H NMR (CDCl3, 300 MHz) 
δ 8.09 (s, 1 H), 7.43-7.35 (m, 3 H), 7.18-7.15 (m, 2 H), 3.74 (s, 3 H), 3.11 (q, 2 H, J = 5.5 Hz), 
2.59 (s, 3 H), 1.20 (t, 3 H, J = 7.4 Hz); 13C NMR (CDCl3, 100 MHz) δ 195.5, 170.7, 151.1, 
148.2, 145.7, 144.2, 129.2, 127.6, 126.1, 108.9, 42.4, 34.7, 14.4, 8.3; IR ν 2934, 1652, 1501 cm-
1; HRMS (ESI+) m/z calculated for C16H17N5OS [M+H]+ 328.1232, found 328.1220. 
 
4c 
Cyclopropyl(4-(methyl(phenyl)amino)-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-8-
yl)methanone (4c). A flame-dried vial was charged with 3 (125 mg, 0.451 mmol, 1.00 equiv.), 
dichloromethane (2.3 mL), cyclopropanecarbonyl chloride (0.084 mL, 0.91 mmol, 2.0 equiv.), 
and tin(IV) chloride (0.27 mL, 2.2 mmol, 5.0 equiv.). The vial was sealed and allowed to heat at 
85 °C for 17 h. The reaction mixture was then poured over crushed ice, diluted with water (8 
mL) and dichloromethane (5 mL) and allowed to stir for 30 min. The layers were separated and 
the aqueous layer was extracted with dichloromethane (10 mL). The combined organic fractions 
were washed with water and brine (10 mL each), dried (MgSO4), and concentrated. Purification 
by chromatography on SiO2 (1:1, hexanes:dichloromethane, then 95:5 to 9:1, 
dichloromethane:ethyl acetate) provided 4c (118 mg, 0.341 mmol, 75%) as a white solid: Mp 
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196.2-198.0 °C; 1H NMR (CDCl3, 300 MHz) δ 8.08 (s, 1 H), 7.44-7.35 (m, 3 H), 7.19-7.15 (m, 2 
H), 3.75 (s, 3 H), 3.46-3.38 (m, 1 H), 2.56 (s, 3 H), 1.22-1.17 (m, 2 H), 1.01-0.95 (m, 2H); 13C 
NMR (CDCl3,125 MHz) δ 194.6, 170.8, 151.5, 148.3, 145.5, 144.2, 129.2, 127.6, 126.1, 109.6, 
42.4, 18.6, 14.4, 11.1; IR ν 3003, 2924, 1586, 1541, 1407 cm-1; HRMS (ESI+) m/z calculated for 
C17H17N5OS [M+H] 340.1232, found 340.1223. 
 
5a 
8-Isopropyl-N-methyl-2-(methylthio)-N-phenylpyrazolo[1,5-a][1,3,5]triazin-4-amine 
(5a).55 To a solution of 4a (378 mg, 1.15 mmol, 1.00 equiv.) in THF (10 mL) at 0 °C under 
nitrogen was added 3M methyl magnesium bromide in diethyl ether (1.2 mL, 3.6 mmol, 3.1 
equiv.) in a dropwise fashion. The reaction was then allowed to stir for 44 min at room 
temperature, quenched with saturated NH4Cl (aq.)(6 mL), and extracted with dichloromethane (5 
mL) and ethyl acetate (2x5 mL). The combined organic layers were washed with brine (12 mL), 
dried (MgSO4), and concentrated. The residue was dissolved in dichloromethane (12 mL) and 
added in a dropwise fashion to solution of NaBH4 (158 mg, 4.18 mmol, 3.63 equiv.) in 
trifluoroacetic acid (12 mL) at 0 °C under nitrogen. The reaction was then allowed to stir for 2 h 
at room temperature and quenched with 1 M NaOH (aq.) (20 mL). The layers were separated and 
the aqueous layer was extracted with dichloromethane (3x10 mL), rinsed with saturated sodium 
bicarbonate (2x20 mL), water (20 mL), and brine (20 mL), dried (MgSO4), and concentrated 
giving 5a (365 mg, 1.10 mmol, 95%) as a yellow-brown oil: 1H NMR (CDCl3, 300 MHz) δ 7.54 
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(s, 1 H) 7.41-7.28 (m, 3 H), 7.18-7.15 (m, 2 H), 3.70 (s, 3 H), 3.13 (septet, 1 H, J = 6.9 Hz), 2.55 
(s, 3 H), 1.27 (d, 6 H, J = 6.9 Hz).  
 
5b 
N-Methyl-2-(methylthio)-N-phenyl-8-propylpyrazolo[1,5-a][1,3,5]triazin-4-amine 
(5b). To a solution of 4b (399 mg, 1.16 mmol, 1.00 equiv.) in dichloromethane/EtOH (1:1, 6.8 
mL) at 0 °C was added LiCl (147 mg, 3.47 mmol, 3.00 equiv.) and NaBH4 (140 mg, 3.66 mmol, 
3.16 equiv.). The reaction mixture was allowed to warm to room temperature, stirred for 17 h, 
quenched with water (5 mL), and extracted with dichloromethane (2x10 mL). The combined 
organic layers were washed with brine (5 mL), dried (MgSO4), and concentrated. The residue 
was then dissolved in dichloromethane (12 mL) and added dropwise to a solution of NaBH4 (442 
mg, 11.5 mmol, 10 equiv.) in trifluoroacetic acid (12 mL) at 0 °C. The reaction mixture was 
allowed to warm to room temperature, stirred for 4 h, quenched with 1 M NaOH (20 mL) and 
diluted with dichloromethane (10 mL). The aqueous layer was then extracted with 
dichloromethane (2x3 mL). The combined organic fractions were washed with saturated sodium 
bicarbonate (2x5 mL) and brine (5 mL), dried (MgSO4) and concentrated giving 5b (331 mg, 
1.00 mmol, 87%) as a yellow oil: 1H NMR (CDCl3, 300 MHz) δ 7.52 (s, 1 H), 7.39-7.29 (m, 3 
H), 7.18-7.15 (m, 2 H), 3.71 (s, 3 H), 2.60-2.55 (m, 2 H), 2.55 (s, 3 H), 1.63 (sextet, 2 H, J = 7.5 
Hz), 0.93 (t, 3 H, J = 7.4 Hz); 13C NMR (CDCl3, 100 MHz) δ 164.9, 148.3, 145.1, 144.8, 128.9, 
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126.9, 126.1, 107.3, 42.0, 24.5, 23.2,14.2, 13.9; IR ν 2954, 1534, 1508 cm-1; HRMS (ESI+) m/z 
calculated for C16H19N5S [M+H]+ 314.1439, found 314.1427. 
 
5c 
8-(Cyclopropylmethyl)-N-methyl-2-(methylthio)-N-phenylpyrazolo[1,5-
a][1,3,5]triazin-4-amine (5c). To a white slurry of 4b (689 mg, 1.91 mmol, 1.0 equiv.) in THF 
(20 mL) was added at 0 °C a 1 M borane solution in THF (4.9 mL, 4.9 mmol, 2.6 equiv.). The 
reaction mixture was stirred for 21 h at room temperature, quenched by the slow addition of 
water (5 mL), and the volume was reduced by half under reduced pressure. The residue was 
extracted with dichloromethane (2x10 mL), and the combined organic fractions were rinsed with 
brine (10 mL), dried (MgSO4), and concentrated giving 5c (258 mg, 0.777 mmol, 41%) as a clear 
oil: 1H NMR (CDCl3, 400 MHz) δ 7.63 (s, 1 H), 7.41-7.30 (m, 3 H), 7.19-7.16 (m, 2 H), 3.71 (s, 
3 H), 2.55 (s, 3 H), 2.55-2.52 (m, 2 H), 0.99-0.92 (m, 1 H), 0.47-0.43 (m, 2 H), 0.21-0.17 (m, 2 
H); 13C NMR (CDCl3, 100 MHz) δ 165.1, 148.3, 145.1, 144.8, 129.2, 128.9, 127.0, 126.1, 107.0, 
42.1, 27.3, 14.2, 11.3, 4.6; IR ν 3070, 2997, 2923, 1534, 1508 cm-1; HRMS (ESI+) m/z calculated 
for C17H19N5S [M+H]+ 326.1439, found 326.1433. 
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6a 
N-Benzyl-8-isopropyl-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-amine (6a).55 A 
flame-dried microwave vial was charged with 5a (84 mg, 0.27 mmol, 1.0 equiv.), benzyl amine 
(0.15 mL, 1.4 mmol, 5.0 equiv.) and ethanol (0.72 mL). The vial was then sealed and allowed to 
heat at 120 °C for 2 h in the microwave, after which time the temperature was increased to 135 
°C for 3 h. Following concentration, purification by chromatography (SiO2, 1:0 to 9:1, 
hexanes:ethyl acetate) provided 6a as a white solid (44 mg, 0.14 mmol, 52%): 1H NMR (CDCl3, 
300 MHz) δ  7.74 (s, 1 H), 7.39-7.28 (m, 5 H), 6.77 (broad s, 1H),  4.80 (d, 2 H, J = 6.0 Hz), 
3.17 (septet, 1 H, J = 6.9 Hz), 2.58 (s, 3 H), 1.33 (d, 6 H, J = 6.9 Hz). 
 
6b 
8-Isopropyl-2-(methylthio)-N-((5-methylthiophen-2-yl)methyl)pyrazolo[1,5-
a][1,3,5]triazin-4-amine (6b).  A flame-dried microwave vial was charged with 5a (80 mg, 0.24 
mmol, 1.0 equiv.), triethylamine (0.67 mL, 0.48 mmol, 20 equiv.), (5-methylthien-2-
yl)methylamine HCl (1935 mg, 1.170 mmol, 4.849 equiv.), KF (15 mg, 0.25 mmol 1.1 equiv.) 
and absolute ethanol (0.80 mL). The vial was then sealed and allowed to heat at 130 °C for 34 h. 
The reaction mixture was then diluted with water (2 mL) and extracted with dichloromethane 
(3x2 mL). The combined organic extracts were washed with brine (2 mL), dried (MgSO4), and 
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concentrated. Purification by chromatography on SiO2 (98:2 to 95:5, hexanes:ethyl acetate) 
provided 6b (41 mg, 0.062 mmol, 49%) as an off white solid: Mp 105.3-105.8°C; 1H NMR 
(CDCl3, 300 MHz) δ 7.72 (s, 1 H), 6.84 (d, 1 H, J = 3.3 Hz), 6.74 (broad s, 1 H), 6.58 (m, 1 H), 
4.85 (d, 2 H, 6.0 Hz), 3.13 (septet, 1 H, J = 6.9 Hz), 2.59 (s, 3 H), 2.44 (s, 3 H), 1.33 (d, 6 H, J = 
6.9 Hz); 13C NMR (CDCl3, 125 MHz) δ 165.7, 145.5, 143.4, 140.6, 136.7, 126.8, 124.8, 115.3, 
39.4, 23.6, 23.2, 15.3, 14.3; IR ν 3286, 2956, 2934,1592, 1564 cm-1; HRMS (ESI+) m/z 
calculated [M+H]+ for C15H19N5S2 334.1160; found 334.1151. 
 
6c 
2-(Methylthio)-N-((5-methylthiophen-2-yl)methyl)-8-propylpyrazolo[1,5-
a][1,3,5]triazin-4-amine (6c). A flame-dried microwave vial was charged with 5b (0.813 g, 2.46 
mmol, 1.00 equiv.), (5-methylthiophen-2-yl)methanamine (1.46 g, 10.9 mmol, 4.44 equiv.), KF 
(0.209 g, 3.56 mmol 1.45 equiv.), and absolute ethanol (8.2 mL). The vial was sealed and heated 
at 130 °C for 20 h. The reaction mixture was diluted with water (10 mL) and extracted with 
dichloromethane (2x10 mL). The combined organic extracts were washed with 1 N HCl (2x10 
mL) and brine (10 mL), dried (MgSO4), and concentrated. Purification by chromatography on 
SiO2 (98:2 then 95:5, hexanes:ethyl acetate) provided 6c (405 mg, 1.19 mmol, 48%) as a white 
solid: Mp 84.9-85.3 °C; 1H NMR (CDCl3, 500 MHz) δ 7.71 (s, 1 H), 6.83 (d, 2 H, J = 1.0 Hz), 
6.79, (bs, 1 H), 6.59-6.58 (m, 1 H), 4.86 (d, 2 H, J = 5.5 Hz), 2.63-2.58 (m, 2 H), 2.60 (s, 3 H), 
2.45 (s, 3 H), 1.68 (sextet, 2 H, J = 7.5 Hz), 0.96 (t, 3 H, J = 7.3 Hz); 13C NMR (CDCl3, 125 
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MHz) δ 166.0, 147.2, 146.2, 145.3, 140.6, 136.7, 126.9, 124.9, 108.8, 39.4, 24.6, 23.3, 15.3, 
14.3, 13.9; IR ν 3247, 2954, 1618, 1588 cm-1; HRMS (ESI+) m/z calculated for C15H19N5S2 
[M+H]+ 334.1160, found 334.1153. 
 
6d 
8-(Cyclopropylmethyl)-2-(methylthio)-N-((5-methylthiophen-2-
yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine (6d). A flame-dried microwave vial was 
charged with 5c (258 mg, 0.753 mmol, 1.00 equiv.), (5-methylthiophen-2-yl)methanamine (445 
mg, 3.43 mmol, 4.55 equiv.), KF (66 mg, 1.13 mmol 1.50 equiv.), and absolute ethanol (2.5 mL). 
The vial was sealed and heated at 130 °C for 24 h. The reaction mixture was diluted with water 
(3 mL), extracted with dichloromethane (2x8 mL), washed with 1 N HCl (5 mL) and brine (5 
mL), dried (MgSO4), and concentrated. Purification by chromatography on SiO2 (95:5 then 92:8, 
hexanes:ethyl acetate) provided 6d (79 mg, 0.22 mmol, 30%) as an off white solid: Mp 105.3-
107.6 °C; 1H NMR (CDCl3, 300 MHz) δ 7.81 (s, 1 H), 6.85 (bs, 1 H), 6.67 (bs, 1 H), 6.60 (d, 1 
H, J = 3.3 Hz), 4.87 (d, 2 H, J = 5.7 Hz), 2.59 (s, 3 H), 2.59-2.56 (m, 2 H), 2.44 (s, 3 H), 1.07-
0.98 (m, 1 H), 0.26-0.21 (m, 2H), 0.52-0.46 (m, 2H); 13C NMR (CDCl3, 125 MHz) δ 166.2, 
147.1, 146.3, 145.2, 140.4, 136.8, 126.6, 124.7, 108.4, 39.3, 27.3,15.2, 14.2, 11.4, 4.6; IR ν 
3232, 2921, 1616, 1584, 12.75 cm-1; HRMS (ESI+) m/z calculated for C16H19N5S2 [M+H]+ 
346.1160, found 346.1154. 
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7a 
N-Benzyl-8-isopropyl-2-(methylsulfonyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine (7a).55 
To a solution of 6a (45 mg, 0.14 mmol, 1.00 equiv.) in acetone (1.0 mL) at 0 °C was added 3.17 
M NaHCO3 (0.36 mL, 1.1 mmol, 7.97 equiv.) followed by oxone in 4x10-4 M EDTA (119 mg in 
0.43 mL, 1.4 equiv.). The reaction was then allowed to stir 5.5 h at room temperature. The 
reaction mixture was quenched with 50% aqueous sodium bisulfite (0.144 mL) and diluted with 
dichloromethane (5 mL). The organic layer was separated and the aqueous phase extracted with 
dichloromethane (2x1 mL), dried (MgSO4), and concentrated. Purification by chromatography 
on SiO2 (4:1, hexanes:ethyl acetate) provided 7a as a clear oil (38 mg, 0.10 mmol, 72%): 1H 
NMR (CDCl3, 300 MHz) δ    7.83 (s, 1 H), 7.30-7.25 (m, 5 H),  4.82 (d, 2 H, 6.0 Hz),  3.29 (s, 3 
H), 3.17 (septet, 1 H, J = 6.9 Hz), 1.27 (d, 6 H, J = 6.9 Hz). 
 
7b 
8-Isopropyl-2-(methylsulfonyl)-N-((5-methylthiophen-2-yl)methyl)pyrazolo[1,5-
a][1,3,5]triazin-4-amine (7b).8  A solution of 6b (23 mg, 0.063 mmol, 1.00 equiv.) acetone (1.0 
mL) at 0 °C was charged with 3.2 M NaHCO3 (0.36 mL, 1.1 mmol, 8.0 equiv.) followed by 0.39 
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M oxone in water (232 mg in 0.8 mL, 3.0 equiv.). The reaction was then allowed to stir 5 h at 
room temperature, quenched with 50% aqueous sodium bisulfite (0.14 mL), and extracted with 
dichloromethane (4x2 mL). The organic layers were washed with brine (2 mL), dried (MgSO4), 
and concentrated giving crude 7b (14.4 mg, 0.0335 mmol, 53%) as a clear oil that was used 
without further purification.  
 
7c 
2-(Methylsulfonyl)-N-((5-methylthiophen-2-yl)methyl)-8-propylpyrazolo[1,5-
a][1,3,5]triazin-4-amine (7c). A solution of 6c (303 mg, 0.890 mmol, 1.00 equiv.) in acetone 
(15 mL) at 0 °C was charged with 0.39 M oxone in water (1620 mg in 6.8 mL, 2.64 mmol 2.96 
equiv.). The reaction mixture was stirred for 12 h at room temperature, quenched with 50% 
aqueous sodium bisulfite (0.48 mL), and the acetone was removed in vacuo. The residue was 
diluted with water (6 mL) and extracted with dichloromethane (3x6 mL). The combined organic 
layers were washed with brine (6 mL), dried (MgSO4), and concentrated giving 7c as a yellow 
oil that was used without further purification. 
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7d 
8-(Cyclopropylmethyl)-2-(methylsulfonyl)-N-((5-methylthiophen-2-
yl)methyl)pyrazolo[1,5-a][1,3,5]triazin-4-amine (7d) A solution of 6d (79 mg, 0.22 mmol, 1.0 
equiv.) in acetone (3.7 mL) at 0 °C was charged with 0.39 M oxone in water (1.7 mL, 0.66 
mmol, 3.0 equiv.). The reaction mixture was stirred for 12 h at room temperature and quenched 
with 50% aqueous sodium bisulfite (0.12 mL) and the acetone was removed in vacuo. The 
residue was diluted with water (3 mL) and extracted with dichloromethane (3x3 mL). The 
combined organic layers were washed with brine (3 mL), dried (MgSO4), and concentrated 
giving 7d as a yellow oil that was used without further purification. 
 
8 
(R)-2-((4-(Benzylamino)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)butan-
1-ol (8).55 A flame-dried microwave vial was charged with 7a (37 mg, 0.10 mmol, 1.0 equiv.), R-
(-)-2-amino-1-butanol (0.048 mL, 0.51 mmol, 5.0 equiv.) and 1,4 dioxane (0.34 mL). The vial 
was sealed and the mixture allowed to heat at 140 °C in a sand bath for 12 h. The solvent was 
then removed and the crude mixture purified by chromatography on SiO2 (2:1, hexanes:ethyl 
acetate) giving 8 as a white solid (30 mg, 0.083 mmol, 82%): 1H NMR (CDCl3, 300 MHz) δ 7.52 
(s, 1 H), 7.27-7.18 (m, 5 H), 6.77 ( broad s, 1 H), 5.04 (broad s, 1 H), 4.62 (dd, 2 H, J = 2.4, 6 
Hz), 3.83 (t, 1 H, 6.6 Hz), 3.75 (d, 1 H, J = 10.5 Hz), 3.59 (dd, 1 H, J = 7.5, 10.8 Hz), 2.94 
(septet, 1 H, J = 6.9 Hz), 1.54 (m, 2 H), 1.20 (dd, 6 H, J = 0.9, 6.9 Hz), 0.95 (t, 3 H, J = 6.5 Hz),. 
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MF-06 
(R)-2-((8-Isopropyl-4-(((5-methylthiophen-2-yl)methyl)amino)pyrazolo[1,5-
a][1,3,5]triazin-2-yl)amino)butan-1-ol (MF-06). A flame-dried microwave vial was charged 
with 7b (50 mg, 0.11 mmol, 1.00 equiv.), R-(-)-2-amino-1-butanol (0.053 mL, 0.055 mmol, 5.0 
equiv.), KF (0.019 mg, 0.32 mmol, 3.0 equiv.) and 1,4 dioxane (0.36 mL). The vial was sealed 
and allowed to heat at 140 °C in a sand bath for 12 h. The reaction mixture was then quenched 
with water (1 mL) and extracted with dichloromethane (2x3 mL). The combined extracts were 
washed with brine (3 mL), dried (MgSO4), and concentrated. Purification by chromatography on 
SiO2 (3:1, dichloromethane:ethyl acetate) provided MF-06 as a viscous yellow oil (28 mg, 0.075 
mmol, 68%): 1H NMR (CDCl3, 300 MHz) δ  7.59 (s, 1 H), 6.88 (broad s, 1H),  6.78 (d, 1 H, J = 
3.3 Hz),  6.57 (m, 1 H), 5.15 (broad s, 1 H),  4.75 (d, 2 H, J = 6.0 Hz),  3.94 (broad s, 1H),  3.84 
(dd, 1 H, J = 2.1, 10.8 Hz), 3.68 (dd, 1 H, J = 7.2, 10.8 Hz),  3.01 (septet, 1 H, J = 6.9 Hz),  1.70-
1.53 (m, 2 H), 2.43 (s, 3 H),  1.27 (d, 6 H, J = 6.9 Hz),  1.04 (t, 3 H, J = 7.4 Hz); 13C NMR 
(CDCl3, 125 MHz) δ, 157.6, 148.5, 146.0, 143.6, 140.4, 137.0, 126.5, 124.8, 112.5, 67.8, 56.2, 
39.3, 24.8,  23.4,  23.1, 15.3, 10.8; IR ν 3288, 2956, 2934, 1631, 1594, 1560 cm-1; HRMS (ESI+) 
m/z calculated [M+H]+ for C18H26N6OS 375.1967; found 375.1955. 
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MF-17 
(R)-2-((4-(((5-Methylthiophen-2-yl)methyl)amino)-8-propylpyrazolo[1,5-
a][1,3,5]triazin-2-yl)amino)butan-1-ol (MF-17). A flame-dried microwave vial was charged 
with 7c (47 mg, 0.011 mmol, 1.00 equiv.), R-(-)-2-amino-1-butanol (0.056 mL, 0.57 mmol, 5.0 
equiv.), KF (34 mg, 0.0.57 mmol, 5.0 equiv.), and 1,4-dioxane (0.31 mL). The vial was sealed 
and heated at 140 °C in a sand bath for 12 h. The reaction mixture was quenched with water (2 
mL) and extracted with dichloromethane (2x3 mL). The combined extracts were washed with 
brine (3 mL), dried (MgSO4), and concentrated. Purification by chromatography on SiO2 (3:1, 
dichloromethane:ethyl acetate) provided MF-17 (25 mg, 0.065 mmol, 57%) as a an off white 
solid: Mp 118.3-120.1 °C; 1H NMR (CDCl3, 300 MHz) δ 7.59 (s, 1 H), 6.82 (d, 1 H, J = 3.3 Hz), 
6.70 (broad s, 1 H), 6.59 (m, 1 H), 4.78 (d, 2 H, J = 6.0 Hz), 3.95 (broad s, 1 H), 3.84 (d, 2 H, J = 
9.6 Hz), 3.68 (dd, 2 H, J = 7.2, 10.8 Hz), 2.49 (t, 2 H, J = 7.4 Hz), 2.44 (s, 3 H), 1.68-1.57 (m, 4 
H), 1.05, (t, 3 H, J = 7.5 Hz), 0.95 (t, 3 H, J = 7.4 Hz ); 13C NMR (CDCl3, 125 MHz) δ 157.7, 
148.4, 146.7, 145.6, 140.4, 137.0, 126.6, 124.8, 105.8, 67.9, 56.3, 39.3, 24.8, 24.5, 23.3, 15.3, 
13.8, 10.8; IR ν 3286, 2956, 2934,1592, 1564 cm-1; HRMS (ESI+) m/z calculated [M+H]+ for 
C18H26N6OS 375.1967, found 375.1960. 
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MF-27 
Ethyl-1-((4-(((5-methylthiophen-2-yl)methyl)amino)-8-propylpyrazolo[1,5-    
a][1,3,5]triazin-2-yl)amino)cyclopropane-1-carboxylate (MF-27). A flame-dried microwave 
vial was charged with 7c (92 mg, 0.24 mmol, 1.00 equiv.), ethyl-1-
aminocyclopropanecarboxylate hydrochloride (203 mg, 1.19 mmol, 4.97 equiv.), KF (70 mg, 1.2 
mmol, 5.0 equiv.), Et3N (0.68 mL, 4.8 mmol, 20 equiv.) and 1,4-dioxane (0.8 mL). The vial was 
sealed and heated at 140 °C in a sand bath for 22 h; an additional portion of Et3N (0.2 mL, 1.42 
mmol, 5.9 equiv.) and 1,4-dioxane (0.4 mL) were added after 10 h. The reaction mixture was 
then treated with water (2 mL) and extracted with dichloromethane (3x3 mL). The combined 
organic extracts were washed with 1 N HCl (3 mL), with brine (3 mL), dried (MgSO4), and 
concentrated. Purification by chromatography on SiO2 (98:2 to 96:4 to 95:5, 
dichloromethane:ethyl acetate) provided MF-27 (12 mg, 0.026 mmol, 11%) as a yellow oil: 1H 
NMR (CDCl3, 300 MHz) δ 7.62 (s, 1 H), 6.80-6.70 (m, 2 H), 6.79 (d, 1 H, J = 3.3 Hz), 6.57 (d, 2 
H, J = 3.3 Hz), 4.78 (d, 2 H, J = 5.7 Hz), 4.13, (q, 2 H, J = 7.1 Hz ), 2.51 (t, 2 H, J = 6.0 Hz), 
2.43 (s, 3 H), 1.67-1.59 (m, 4 H), 1.27-1.20 (m, 6 H), 1.20 (t, 3 H, J = 7.0 Hz) 0.93 (t, 3 H, J = 
7.4 Hz); 13C NMR (CDCl3, 125 MHz) δ 173.4, 157.4, 148.6, 145.7, 140.4, 137.0, 126.7, 124.8, 
106.1, 61.1, 39.3, 35.4, 24.5, 23.3, 18.4, 15.3, 14.3, 13.8; IR ν 3188, 2953, 2923, 1726 1663, 
1596 cm-1; HRMS (ESI+) m/z calculated for C20H26N6O2S [M+H]+ 415.1916, found 415.1909. 
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MF-59 
(S)-3,3,3-Trifluoro-2-((4-(((5-methylthiophen-2-yl)methyl)amino)-8-
propylpyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)propan-1-ol (MF-59). A flame-dried 
microwave vial was charged with 7c (49 mg, 0.12 mmol, 1.0 equiv.), (S)-trifluoroalaninol5 (99 
mg, 0.59 mmol, 4.9 eq.), KF (35 mg, 0.60 mmol, 5.0 equiv.), Et3N (0.34 mL, 2.4 mmol, 20 
equiv.), and 1,4 dioxane (0.48 mL). The vial was sealed and heated at 100 °C in an oil bath for 
13 h and for 10 h at 120 °C. The reaction mixture was then treated with water (2 mL) and 
extracted with dichloromethane (2x3 mL). The combined organic extracts were washed with 
brine (3 mL), dried (MgSO4), and concentrated. Purification by chromatography on SiO2 (1:0, to 
9:1, to 5:1, dichloromethane:ethyl acetate) provided MF-59 (22 mg, 0.052 mmol, 43%) as a clear 
oil: 1H NMR (CDCl3, 300 MHz) δ 7.72 (s, 1 H), 6.91 (t, 1 H, J = 5.4 Hz), 6.83 (d, 2 H, J = 3.3 
Hz), 6.60-6.58 (m, 1 H), 4.86 (d, 2 H, J = 5.7 Hz), 4.68 (dd, 1 H, J = 3.9, 11.0 Hz), 4.46 (dd, 1 H, 
J = 7.5 Hz, 11.0 Hz), 3.79 (ddq, 1 H, J = 3.9, 3.9, 7.5 Hz), 2.57 (t, 3 H, J = 7.5 Hz), 2.44 (s, 3 H), 
1.76 (bs, 2 H), 1.65 (sextet, 2 H, J = 7.4 Hz), 0.95 (t, 3 H, J = 7.4 Hz); 13C NMR (CDCl3, 125 
MHz) δ 160.0, 149.7, 146.6, 146.1, 140.7, 136.3, 128.9, 126.9,125.5 (q, J = 280 Hz), 124.9, 
108.6, 65.8, 53.3 (q, J = 28 Hz), 39.6, 24.4, 23.3, 15.3, 13.8; IR ν 3291, 2956, 2928, 2869, 1632, 
1596, 1128 cm-1; HRMS (ESI+) m/z calculated for C17H21F3N6OS [M+H]+ 415.1528, found 
415.1520. 
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MF-21 
2-Methyl-2-((4-(((5-methylthiophen-2-yl)methyl)amino)-8-propylpyrazolo[1,5-
a][1,3,5]triazin-2-yl)amino)propan-1-ol (MF-21). A flame-dried vial was charged with 7d (107 
mg, 0.26 mmol, 1.0 equiv.), 2-amino-2-methyl-1-propanol (124 mg, 1.32 mmol, 5.0 equiv.), KF 
(77 mg, 1.32 mmol, 5.0 equiv.), and 1,4-dioxane (1.0 mL). The vial was sealed and heated in an 
oil bath for 18 h at 120 °C. The reaction mixture was treated with water (4 mL) and extracted 
with dichloromethane (2x10 mL). The combined organic layers were washed with brine (3 mL), 
dried (MgSO4), and concentrated. Purification by chromatography on SiO2 (1:0 to 4:1, 
dichloromethane:ethyl acetate) provided MF-71 (21 mg, 0.053 mmol, 27%) as a clear oil: 1H 
NMR (CDCl3, 400 MHz) δ 7.59 (s, 1 H), 6.82 (d, 1 H, J = 3.2 Hz), 6.65 (bs, 1 H), 6.60 (d, 1 H, J 
= 2.4 Hz), 5.14 (bs, 1 H), 4.76 (d, 2 H, J = 6.0 Hz), 3.71 (d, 2 H, J = 6.0 Hz), 2.49 (t, 2 H, J = 6.6 
Hz), 2.45 (s, 3 H), 1.65-1.59 (m, 3 H), 1.40 (s, 6 H), 0.94 (t, 3 H, J = 7.4 Hz); 13C NMR (CDCl3, 
125 MHz) δ 156.4, 148.3, 146.1, 145.5, 140.4, 136.8, 126.5, 124.8, 106.0, 71.9, 55.8, 39.3, 25.3, 
24.5, 23.4, 15.3, 13.8; IR ν 3256, 2956, 2922, 1591, 1560 cm-1; HRMS (ESI+) m/z calculated for 
C18H27N6OS [M+H]+ 375.1967, found 387.1956. 
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MF-71 
(R)-2-((8-(Cyclopropylmethyl)-4-(((5-methylthiophen-2-
yl)methyl)amino)pyrazolo[1,5-a][1,3,5]triazin-2-yl)amino)butan-1-ol (MF-71). 
A flame-dried vial was charged with 7d (84 mg, 0.20 mmol, 1.0 equiv.), (R)-(-)-2-amino-
1-butanol (0.095 mL, 1.0 mmol, 5.0 equiv.), KF (59 mg, 1.0 mmol, 5.0 equiv.), and 1,4-dioxane 
(0.67 mL). The vial was sealed and heated in an oil bath for 10 h at 120 °C. The reaction mixture 
was treated with water (2 mL) and extracted with dichloromethane (2x3 mL). The combined 
organic layers were washed with 1 N HCl (2 mL) and brine (3 mL), dried (MgSO4), and 
concentrated. Purification by chromatography on SiO2 (5:1 to 3:1, dichloromethane:ethyl 
acetate) provided MF-71 (21 mg, 0.053 mmol, 27%) as a clear oil: 1H NMR (CDCl3, 400 MHz) 
δ 7.68 (s, 1 H), 6.83 (bs, 1 H), 6.79 (d, 1 H, J = 3.2 Hz), 6.58 (d, 1 H, J = 2.4 Hz), 5.13 (bs, 1 H), 
4.76 (d, 2 H, J = 5.6 Hz), 3.95 (bs, 1 H), 3.83 (dd, 2 H, J = 2.0, 11 Hz), 3.67 (dd, 2 H, J = 7.2, 11 
Hz), 2.46-2.40 (m, 2 H), 2.42 (s, 3 H), 1.70-1.59 (m, 2 H), 1.06-0.94 (m, 4 H), 0.49-0.45 (m, 2 
H), 0.20-0.16 (m, 2 H); 13C NMR (CDCl3, 125 MHz) δ 157.9, 148.5, 146.8, 145.5, 140.4, 137.0, 
126.5, 124.8, 105.4, 67.9, 56.2, 39.3, 27.2, 24.8, 15.3, 11.4, 10.8, 4.5, 4.5; IR ν 3340, 3292, 
2960, 1633, 1592, 1562 cm-1; HRMS (ESI+) m/z calculated for C19H26N6OS [M+H]+ 387.1967, 
found 387.1965. 
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N
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N
H
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N
U
C1                13C
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
D11          0.03000000 sec
D1           4.00000000 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 298.8 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16.800 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 203
AQ            1.1010548 sec
F
I
D
R
ES         0.454131 Hz
SWH           29761.904 Hz
DS                    4
NS                 8192
SOLVENT           CDCl3
T
D
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P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
z
g
p
g30
P
R
O
B
H
D
 
 
 5 mm PABBO BB
−
I
NSTRUM           spect
Time               6.50
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20140121
F2 
−
 
A
c
q
uisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
N
A
M
E
 
 
 
 
 
mf
−00562
−027_f2
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
mf
−00562
−027_f2 125 MHz
N
N
N
N
H
N
NH
O
E
t
S
O
M
F-27 
 59 
10
9
8
7
6
5
4
3
2
1
ppm 0.926
0.950
0.975
1.592
1.617
1.641
1.666
1.691
1.716
1.765
2.437
2.542
2.567
2.592
3.760
3.773
3.785
3.798
3.810
3.823
4.433
4.459
4.471
4.496
4.655
4.668
4.693
4.706
4.855
4.874
6.586
6.589
6.593
6.597
6.600
6.826
6.837
6.892
6.911
6.928
7.260
7.716
3.31
2.52
1.85
3.22
2.16
1.06
1.07
1.09
2.22
1.02
1.06
1.01
1.00
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.10 Hz
SSB                   0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
SF          300.2300085 MHz
SI                32768
P1                12.71 usec
N
U
C1                 1H
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
D1           1.00000000 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
−926.4 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 80.800 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 128
AQ            2.6477044 sec
F
I
D
R
ES         0.188846 Hz
SWH            6188.119 Hz
DS                    2
NS                   16
SOLVENT           CDCl3
T
D
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P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
 
 
z
g30
P
R
O
B
H
D
 
 
 5 mm QNP  1H/1
I
NSTRUM           spect
Time              14.34
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20140213
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10
N
A
M
E
 
 
 
 
 
mf
−00562
−059_f1
mf
−00562
−059_f1 300MHz
N
N
N
N
H
N
NH
O
H
S
C
F
3
M
F-59 
 60 
200
180
160
140
120
100
80
60
40
20
0
ppm
13.80
15.30
23.30
24.44
39.57
52.91
53.14
53.37
53.60
65.82
76.74
77.00
77.25
108.64
122.16
124.40
124.93
126.63
126.91
128.87
136.25
140.70
146.14
146.60
149.65
159.98
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.40
G
B
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00 Hz
SSB      0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
SF          125.7653362 MHz
SI                32768
F2 
−
 
P
r
o
c
e
s
sing parameters
SFO2        500.1620006 MHz
P
L
W13    0 W
P
L
W12        0.36736000 W
P
L
W2        18.74300003 W
P
C
P
D2             80.00 usec
N
U
C2                 1H
C
P
D
P
R
G2         waltz16
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f2 ========
SFO1        125.7779080 MHz
P
L
W1       112.58000183 W
P1                 8.80 usec
N
U
C1                13C
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
D11          0.03000000 sec
D1           4.00000000 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 298.4 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16.800 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 203
AQ            1.1010548 sec
F
I
D
R
ES         0.454131 Hz
SWH           29761.904 Hz
DS                    4
NS                 8344
SOLVENT           CDCl3
T
D
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R
O
G
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R
O
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H
D
 
 
 5 mm PABBO BB
−
I
NSTRUM           spect
Time               6.59
D
a
t
e
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 20140215
F2 
−
 
A
c
q
uisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2
N
A
M
E
 
 
 
 
 
 
 
mf
−00562
−059
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
mf
−00562
−059 125MHz
N
N
N
N
H
N
NH
O
H
S
C
F
3
M
F-59 
 61 
10
9
8
7
6
5
4
3
2
1
0
ppm
0.921
0.940
0.958
1.402
1.452
1.589
1.608
1.626
1.645
2.043
2.445
2.477
2.496
2.514
3.275
3.700
3.715
4.110
4.128
4.754
4.769
5.137
6.594
6.600
6.653
6.811
6.819
7.260
7.587
3.20
0.29
6.01
2.99
0.13
3.04
2.07
0.13
2.00
0.11
2.12
0.72
1.98
1.07
1.00
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.30 Hz
SSB                  
 0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
SF          400.1300096 MHz
SI                65536
P1                13.75 usec
N
U
C1                 1H
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
D1           1.00000000 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 94.3 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60.800 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 128
AQ            3.9846387 sec
F
I
D
R
ES         0.125483 Hz
SWH            8223.685 Hz
DS                   
 2
NS                   16
SOLVENT           CDCl3
T
D
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U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
 
 
z
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R
O
B
H
D
 
 
 5 mm PABBO BB
−
I
NSTRUM           spe
ct
Time               9.23
D
a
t
e
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 20140429
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20
N
A
M
E
 
 
 
 
 
 
 
mf
−00581
−021
mf
−00581
−021 400A
N
N
N
N
HN
NH
OH
S
M
F-21 
 62 
200
180
160
140
120
100
80
60
40
20
0
ppm
13.75
15.31
23.37
24.47
25.28
39.27
55.82
71.92
76.75
77.00
77.25
106.02
124.83
126.49
136.83
140.41
145.49
146.09
148.30
156.37
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.40
G
B
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00 Hz
S
SB   
   0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
S
F    
      125.7653371 MHz
S
I    
       
     32768
F2 
−
 
P
r
o
c
e
s
sing parameters
S
FO2        500.1620006 MHz
P
L
W13    0 W
P
L
W12        0.36736000 W
P
L
W2        18.74300003 W
P
C
P
D2             80.00 usec
N
U
C2                 1H
C
P
D
P
R
G2         waltz16
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f2 ========
S
FO1        125.7779080 MHz
P
L
W1       112.58000183 W
P1                 8.80 usec
N
U
C1                13C
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
D11          0.03000000 sec
D1           3.00000000 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 298.0 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16.800 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 203
AQ            1.1010548 sec
F
I
D
R
ES
       
  0.454131 Hz
S
WH   
       
 29761.904 Hz
D
S    
       
     
    4
N
S    
       
     
 2617
S
OLVEN
T      
     
CDCl3
T
D
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G
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p
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H
D
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−
I
NSTRU
M      
     
spect
Time               8.58
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20140429
F2 
−
 
A
c
q
uisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
N
A
M
E
 
 
 
 
 
 
 
mf
−00581
−020
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
mf
−00581
−021 125 MHz
N
N
N
N
HN
NH
OH
S
M
F-21 
 63 
10
9
8
7
6
5
4
3
2
1
0
ppm 0.164
0.176
0.187
0.199
0.446
0.456
0.459
0.466
0.476
0.489
0.962
0.964
0.969
0.981
0.993
0.998
1.019
1.038
1.056
1.568
1.585
1.603
1.622
1.640
1.656
1.674
2.431
2.439
2.446
2.457
2.463
3.648
3.666
3.676
3.694
3.822
3.845
3.850
4.754
4.768
6.572
6.578
6.786
6.794
6.832
7.260
7.677
2.12
2.11
4.35
0.15
2.10
5.18
1.09
1.09
0.95
2.09
1.18
1.00
2.00
1.00
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00
G
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0.30 Hz
SSB                   0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
SF          400.1300104 MHz
SI                65536
P1                13.75 usec
N
U
C1                 1H
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
D1           1.00000000 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 309.8 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60.800 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 80.6
AQ            3.9846387 sec
F
I
D
R
ES         0.125483 Hz
SWH            8223.685 Hz
DS                    2
NS                   16
SOLVENT           CDCl3
T
D
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P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
 
 
z
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P
R
O
B
H
D
 
 
 5 mm PABBO BB
−
I
NSTRUM           spect
Time               1.08
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20140305
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21
N
A
M
E
 
 
 
 
 
 
 
mf
−00562
−071
mf
−00562
−071 400A
N
N
N
N
H
N
NH
O
H
S
M
F-71 
 64 
 
200
180
160
140
120
100
80
60
40
20
0
ppm
4.49
4.52
10.81
11.35
15.30
24.80
27.15
39.29
56.16
67.91
76.75
77.00
77.25
105.41
124.80
126.52
137.00
140.39
145.52
146.81
148.45
157.87
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.40
G
B
 
 
 
 
 
 
 0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.00 Hz
S
SB
    
 
 0
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
S
F 
    
 
    125.7653352 MHz
S
I 
    
 
    
 
    
 32768
F2 
−
 
P
r
o
c
e
s
sing parameters
S
FO2        500.1620006 MHz
P
L
W13    0 W
P
L
W12        0.36736000 W
P
L
W2        18.74300003 W
P
C
P
D2             80.00 usec
N
U
C2                 1H
C
P
D
P
R
G2         waltz16
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f2 ========
S
FO1        125.7779080 MHz
P
L
W1       112.58000183 W
P1                 8.80 usec
N
U
C1                13C
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 f1 ========
D11          0.03000000 sec
D1           4.00000000 sec
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 299.3 K
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6.50 usec
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16.800 usec
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 203
AQ            1.1010548 sec
F
I
D
R
ES 
 
    
 
  0.454131 Hz
S
WH
    
 
    
 
 29761.904 Hz
D
S 
    
 
    
 
    
 
    4
N
S 
    
 
    
 
    
 
 7024
S
OL
VENT
 
    
 
    
 
CDCl3
T
D
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P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
z
g
p
g30
P
R
O
B
H
D
 
 
 5 mm PABBO BB
−
I
NS
TRUM
 
    
 
    
 
spec
t
Time               7.13
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 20140306
F2 
−
 
A
c
q
uisition Parameters
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1
N
A
M
E
 
 
 
 
 
 
 
M
F
−00562
−071
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
mf
−00562
−071N
N
N
N
H
N
NH
O
H
S
M
F-71 
